In a study of patients with advanced melanoma treated with single-agent nivolumab or pembrolizumab, 25.8% achieved a complete response (CR). Approximately four out of five patients with advanced melanoma that discontinued treatment after achieving a complete response (CR) with single-agent anti-PD-1 immunotherapy remained alive after 3 years, researchers reported.

Learn more by clicking here.